Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

被引：12
|
作者：
Srinivasan, Ramaprasad
Donskov, Frede
Iliopoulos, Othon
Rathmell, Wendy Kimryn
Narayan, Vivek
Maughan, Benjamin L.
Oudard, Stephane
Else, Tobias
Maranchie, Jodi K.
Welsh, Sarah Joanne
Roy, Ananya
Liu, Yanfang
Perini, Rodolfo F.
Linehan, W. Marston
Jonasch, Eric
机构：
[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Harvard Med Sch, Boston, MA 02115 USA
[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[6] Univ Penn, Philadelphia, PA 19104 USA
[7] Univ Utah, Salt Lake City, UT USA
[8] Hop Europeen Georges Pompidou, Paris, France
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Univ Pittsburgh, Pittsburgh, PA USA
[11] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
[12] Merck & Co Inc, Kenilworth, NJ USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4555
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase II study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
    Iliopoulos, Othon
    Jonasch, Eric
    Donskov, Frede
    Narayan, Vivek
    Maughan, Benjamin Louis
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah J.
    Thamake, Sanjay
    Perini, Rodolfo F.
    Park, Eric Kristopher
    Linehan, Marston W.
    Srinivasan, Ramaprasad
    Rathmell, Kimryn W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [2] Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.
    Jonasch, Eric
    Donskov, Frede
    Iliopoulos, Othon
    Rathmell, Wendy Kimryn
    Narayan, Vivek
    Maughan, Benjamin Louis
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah J.
    Thamake, Sanjay
    Park, Eric Kristopher
    Zojwalla, Naseem J.
    Perini, Rodolfo F.
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)
    McDermott, D. F.
    Choueiri, T. K.
    Bauer, T. M.
    Arrowsmith, E.
    Roy, A.
    Perini, R.
    Vickery, D.
    Tykodi, S. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S681 - S681
  • [4] Phase II study of the oral HIF-2a inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
    Srinivasan, R.
    Donskov, F.
    Iliopoulos, O.
    Rathmell, W. K.
    Narayan, V. K.
    Maughan, B. L.
    Oudard, S.
    Else, T.
    Maranchie, J. K.
    Welsh, S. J.
    Thamake, S.
    Park, E. K.
    Perini, R. F.
    Linehan, W. M.
    Jonasch, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S1158 - S1158
  • [5] Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Tykodi, Scott S.
    Bauer, Todd Michael
    McDermott, David F.
    Arrowsmith, Edward
    Zojwalla, Naseem J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] Phase 2 study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
    Choueiri, Toni K.
    Bauer, Todd Michael
    McDermott, David F.
    Arrowsmith, Edward
    Roy, Ananya
    Perini, Rodolfo F.
    Vickery, Donna
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [7] MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma
    Hasanov, Elshad
    Jonasch, Eric
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (05) : 495 - 504
  • [8] Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Fan, Li
    Perini, Rodolfo F.
    Zojwalla, Naseem J.
    Powles, Thomas
    Rini, Brian, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease
    Wiley, Henry
    Coleman, Hanna
    Jonasch, Eric
    Srinivasan, Ramaprasad
    Donskov, Frede
    Kruse, Anders
    Maranchie, Jodi
    Chhablani, Jay
    Else, Tobias
    Demirci, Hakan
    Maughan, Benjamin
    Hartnett, Mary
    Perini, Rodolfo
    Park, Eric
    Chew, Emily
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [10] Belzutifan, an oral hypoxia-inducible factor 2α inhibitor, for Von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors
    Else, T.
    Jonasch, E.
    Iliopoulos, O.
    Rathmell, W. K.
    Narayan, V. K.
    Maughan, B. L.
    Oudard, S.
    Fu, W.
    Liu, Y.
    Perini, R. F.
    Linehan, W. M.
    Srinivasan, R.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 172 - 172
12345